Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Neurosense Therapeutics News

Aktie
WKN:  A3DFK1 ISIN:  IL0011809592 US-Symbol:  NRSN Branche:  Biotechnologie Land:  Israel
0,721 $
+0,0009 $
+0,12%
0,6129 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
16,72 Mio. €
Streubesitz
72,74%
KGV
-2,73
Index-Zuordnung
-

Neurosense Therapeutics News

06.04.26 - PR Newswire
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Granted Brazilian Patent Covering PrimeC Composition PR Newswire
03.04.26 - PR Newswire
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements PR Newswire
31.03.26 - PR Newswire
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PR Newswire
24.03.26 - PR Newswire
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout PR Newswire
18.03.26 - PR Newswire
/C O R R E C T I O N -- NeuroSense/
/C O R R E C T I O N -- NeuroSense/ PR Newswire
16.03.26 - PR Newswire
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity PR Newswire
09.03.26 - PR Newswire
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PR Newswire
18.02.26 - PR Newswire
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS PR Newswire
09.02.26 - PR Newswire
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition PR Newswire
21.01.26 - PR Newswire
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire
08.01.26 - PR Newswire
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
World-​Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire
22.12.25 - PR Newswire
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study PR Newswire
04.12.25 - PR Newswire
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire
24.11.25 - PR Newswire
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire
03.11.25 - PR Newswire
NeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense to Host Investor Webinar on December 8, 2025 PR Newswire
06.10.25 - PR Newswire
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers PR Newswire
10.09.25 - PR Newswire
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-​Derived Neurons PR Newswire
04.09.25 - PR Newswire
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price PR Newswire
01.08.25 - PR Newswire
NeuroSense Provides Business Update and Progress for the First Half of 2025
NeuroSense Provides Business Update and Progress for the First Half of 2025 PR Newswire
22.07.25 - PR Newswire
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
Award-​Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization ...

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »